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CENTRAL NERVOUS SYSTEM TUMORS
Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A
systematic review and meta-analysis of numbers needed to treat.
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Background: The optimal role of chemotherapy and radiation (RT) in adult low-grade glioma (LGG, WHO grade 1 & 2) is unclear.
We conducted a systematic review and study-level meta-analysis of the literature on overall survival (OS) and progression free
survival (PFS) in patients with LGG. Methods: Pubmed was queried with MeSH terms. All comparative studies of adults with
newly diagnosed, supratentorial LGG were included. Comparisons of interest were OS and PFS at 2, 5, and 10 years in
chemotherapy versus no chemotherapy and early RT versus delayed or no RT. Data were extracted from studies and
synthesized with a random effects model. Quality of evidence was determined by American Academy of Neurology criteria and
further analysis was performed, separating high quality (class I and II) from low quality (class III and IV) evidence. Numbers
needed to treat (NNT) were determined from the risk difference. Results: 1531 articles were screened; 18 studies were included.
Chemotherapy was not associated with a significant survival advantage compared to control. However, an analysis of high
quality data revealed a survival advantage at 10 years associated with chemotherapy compared to control with NNT 5 (relative
risk death chemo vs control 0.69 [0.56-0.86] p = 0.0006). Furthermore, NNT to prevent one progression with chemotherapy at 5
and 10 years was 6 and 3, respectively. Early RT was not associated with an OS advantage compared to control. However, early
RT had progression benefit at all time points, with NNT of 10, 6, and 5 at 2, 5, and 10 years. Conclusions: Further study will be
needed to confirm the optimal role of chemotherapy and RT. Caution must be used in interpretation as much of the literature
consists of low-quality studies.
N
(studies)
N
(participants)
RR progression  
(intervention vs
control)
Lower
95% CI
Upper
95% CI P
NNT
(95%
CI)
5 Year Progression, Chemo vs
Control 3 431 0.69 0.55 0.87 0.001 6 (4-12)
10 Year Progression, Chemo vs
Control 3 431 0.58 0.39 0.87 0.008 3 (2-10)
2 Year Progression Early RT vs
Control 6 1473 0.66 0.51 0.86 0.002 10 (5-50)
5 Year Progression Early RT vs
Control 6 1473 0.73 0.61 0.88 0.0008 6 (4-15)
10 Year Progression Early RT vs
Control 4 1114 0.74 0.60 0.91 0.005 5 (3-17)
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